Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on January 29, 2015. The registrant is a foreign private issuer reporting pursuant to Rule 13A-16 or 15D-16 under the Securities Exchange Act of 1934. The filing serves to distribute a news release regarding the company's scheduled presentation at the BIO CEO & Investor Conference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate a news release and does not contain financial statements or quantitative performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document contains no comparative data versus prior periods.
Guidance, Outlook, and Risks
The primary content of this filing is the announcement that Aurinia Pharmaceuticals will present at the BIO CEO & Investor Conference. The filing does not contain specific guidance, management commentary on financial outlook, risk factors, contingencies, or unusual items beyond the conference announcement.
Key Facts for Investor Verification
- The filing is a Form 6-K dated January 29, 2015, signed by Michael R. Martin, Chief Operating Officer.
- The filing references Exhibit 99.1, a news release concerning the BIO CEO & Investor Conference presentation.
- No financial data is included in this specific document; investors should refer to the referenced news release or the company's Form 40-F for financial details.